Anti-Acetylated Histone/p53 (Lys382) mAb

  • Applications
    • ELISA
    • IF
    • WB
  • Target p53
  • Host Species Mouse
  • Species Reactivities Human
  • Code # CY-M1029
  • Size 100 μg
  • Price
    $401.02
Specifications

Background

Acetylation and deacetylation of nucleosomal histones play an important role in the modulation of chromatin structure, chromatin function and in the regulation of gene expression. Histone acetyltransferases (HATs) and histone deacetylases (HDACs) are two opposing classes of enzymes, which tightly control the equilibrium of histone acetylation. An imbalance in the equilibrium of histone acetylation has been associated with carcinogenesis and cancer progression. So far, a number of structurally distinct classes of compounds have been identified as HDAC inhibitors including the short-chain fatty acids, hydroxamates, cyclic tetrapeptides and benzamides. These compounds lead to an accumulation of acetylated histone proteins both in tumor cells and in normal tissues. HDAC inhibitors are able to activate differentiation, to arrest the cell cycle in G1 and/or G2, and to induce apoptosis in transformed or cancer cells. Attention is currently being drawn to molecular mechanisms involving histone deacetylases. An induction of p21WAF1 and a suppression of angiogenic stimulating factors have been observed in tumor cells following exposure to HDAC inhibitors. In xenograft models, several HDAC inhibitors have demonstrated antitumor activity with only few side effects. Several clinical trials showed that HDAC inhibitors in well-tolerated doses have significant antitumoral activities. A combination of HDAC inhibitors with differentiation-inducing agents and cytotoxic drugs is an innovative therapeutic strategy that carries the potential for significant improvements in the treatment of cancer.
  • Antibody Type:
    Monoclonal
  • Application:
    ELISA, IF, WB
  • Clone Number:
    TM-5C5
  • Concentration:
    1.0 mg/mL
  • Conjugate:
    Unlabeled
  • Description:

    Monoclonal Antibody of 100 μg targeting p53 for ELISA, IF, WB.

  • Formulation:
    Supplied in 20mM phosphatase buffer (pH 7.5), 300mM NaCl, 50% glycerol.
  • Host Species:
    Mouse
  • Immunogen:
    Acetylated peptide synthesis near Lys382 of human p53 (binding KLH)
  • Isotype:
    IgG1
  • Product Type:
    Antibody
  • Reactivity:
    The Acetylated Histone/p53 (Lys382) Monoclonal Antibody (TM-5C5) detects endogenous acetylated Histones (14.4-21.5 kDa) and several acetylated protein including acetylated p53 (acetylated lysine 382) . The antibody does not recognize non-acetylated Histo
  • Research Area:
    Cancer
  • Short Description:

    Anti-Acetylated Histone/p53 (Lys382) Monoclonal Antibody.

  • Size:
    100 μg
  • Species Reactivity:
    Human
  • Storage Temperature:
    -20°C
  • Target:
    p53
Citations
  1. Li Y, Matsumori H, Nakayama Y, Osaki M, Kojima H, Kurimasa A, Ito H, Mori S, Katoh M, Oshimura M, Inoue T.; SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis. Genes Cells. 16:34-45. 2011
References
  1. Davie, J. R & Chadee, D. N. J. Cell Biochem. (Suppl.) 30-31, 203-213, 1998
  2. Kouzarides, T. Curr. Opin. Genet. Dev. 9, 40-84, 1999
  3. Fenrick, R. & Hiebert, S.W. J. Cell Biochem. (Suppl.) 30-31, 194-202, 1998
  4. Yoshida, M., Horinouchi, S. & Beppu, T. Bioassays 17, 423-430, 1995
  5. Richon, V. M. et al. Proc. Natl. Acad. Sci. USA 93, 5705-5708, 1996
  6. Richon, V. M. et al. Proc. Natl. Acad. Sci. USA 95, 3003-3007, 1998
  7. Cohen, L. et al. Proc. AACR 39, 108, abstr. 736, 1998
  8. Desai, D., El-Bayoumy, K. & Amin, S. Proc. AACR 40, 2396, abstr. 362, 1999
  9. Laherty, C. D., Yang, W-M. et al Cell 89, 349-356, 1997
  10. Hassig, C., Fleischer, T. C. et al Cell 89, 341-347, 1997
  11. Hoffmann, K., Grosch, G. & Jung, M. Nucleic Acids Res. 27, 2057-2058, 1999